NanoViricides, Inc. (NYSE American: NNVC) announced it is awaiting regulatory approval to initiate a Phase II clinical trial of its NV-387 Oral Gummies for the treatment of Bundibugyo ebolavirus in the Democratic Republic of the Congo (DRC). The company has submitted an application to the local regulatory agency and secured financing to support the study, which aims to address the ongoing Ebola outbreak where no approved treatment or vaccine exists for the Bundibugyo strain.
NV-387 is the only orally administered Ebola treatment candidate currently under consideration for clinical testing, according to NanoViricides. The company believes its broad-spectrum antiviral mechanism could offer significant advantages over infusion-based therapies in resource-limited outbreak settings. Sufficient quantities of the drug are already in the DRC to support the planned study, pending regulatory approval.
The trial represents a critical step in addressing a public health gap. The Bundibugyo ebolavirus outbreak has no approved countermeasures, making any potential treatment a priority. NanoViricides' oral formulation could simplify administration, reduce the need for cold chain logistics, and enable broader access in remote areas. If successful, NV-387 could become a key tool in future Ebola responses.
NanoViricides is a clinical-stage company focused on creating special purpose nanomaterials for antiviral therapy. Its lead drug candidate, NV-387, is a broad-spectrum antiviral being developed for RSV, COVID-19, Long COVID, influenza, MPOX, smallpox, and measles. The company's technology is based on intellectual property licensed from TheraCour Pharma, Inc.
The company's pipeline also includes NV-HHV-1 for shingles and two COVID-19 candidates: NV-CoV-2 (API NV-387) and NV-CoV-2-R (NV-387 encapsulating remdesivir). The company believes the latter could be an approvable drug given remdesivir's FDA approval.
Investors can find the latest news and updates on NanoViricides at https://ibn.fm/NNVC. The full press release is available at https://ibn.fm/t1kLC.
The DRC's approval of this trial could pave the way for a novel oral treatment option against Ebola, potentially transforming outbreak management. The drug's broad-spectrum activity also suggests it could be repurposed for other viral threats, offering long-term public health benefits.
